Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangfang Lai

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
European Journal of Medicinal Chemistry|February 5, 2025
Design and synthesis of novel sulfur-substituted triptolide with the ability to induce autophagy through inhibition of SRSF1 expressionXinyi Chen, Jichen Guan, Yuzhi Lin, et al.
Molecules (Basel, Switzerland)|June 15, 2019
Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor AgentsHui Wen, Yuke Liu, Shufang Wang, et al.
Cellular and Molecular Life Sciences : CMLS|April 14, 2019
Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancerNina Xue, Fangfang Lai, Tingting Du, et al.
European Journal of Medicinal Chemistry|March 19, 2026
Novel nitric oxide-releasing triptolidenol derivatives suppress gastric cancer by targeting the folate one-carbon metabolism pathway and inducing ROS accumulationYulu Tian, Jichen Guan, Haowen Luo, et al.
BMJ Open Diabetes Research & Care|August 26, 2021
Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adultsJunfeng Zhang, Qiaoyan Xu, Fangfang Lai, et al.
European Journal of Medicinal Chemistry|February 7, 2020
Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studiesYingda Zang, Fangfang Lai, Junmin Fu, et al.
Bioorganic & Medicinal Chemistry|August 24, 2025
Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interactionYang Yang, Meiqin Xu, Ke Wang, et al.
Oncotargets and Therapy|July 10, 2018
CAT<sub>3</sub>, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O<sup>6</sup>-methylguanine DNA methyltransferase expressionMing Ji, Liyuan Wang, Ju Chen, et al.
Free Radical Biology & Medicine|April 8, 2014
Involvement of Na/K-ATPase in hydrogen peroxide-induced activation of the Src/ERK pathway in LLC-PK1 cellsYu Wang, Qiqi Ye, Changxuan Liu, et al.
Acta Pharmaceutica Sinica. B|July 31, 2023
Erratum: Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858]Fangfang Lai, Ming Ji, Lei Huang, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
European Journal of Medicinal Chemistry|February 5, 2025
Design and synthesis of novel sulfur-substituted triptolide with the ability to induce autophagy through inhibition of SRSF1 expressionXinyi Chen, Jichen Guan, Yuzhi Lin, et al.
Molecules (Basel, Switzerland)|June 15, 2019
Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor AgentsHui Wen, Yuke Liu, Shufang Wang, et al.
Cellular and Molecular Life Sciences : CMLS|April 14, 2019
Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancerNina Xue, Fangfang Lai, Tingting Du, et al.
European Journal of Medicinal Chemistry|March 19, 2026
Novel nitric oxide-releasing triptolidenol derivatives suppress gastric cancer by targeting the folate one-carbon metabolism pathway and inducing ROS accumulationYulu Tian, Jichen Guan, Haowen Luo, et al.
BMJ Open Diabetes Research & Care|August 26, 2021
Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adultsJunfeng Zhang, Qiaoyan Xu, Fangfang Lai, et al.
European Journal of Medicinal Chemistry|February 7, 2020
Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studiesYingda Zang, Fangfang Lai, Junmin Fu, et al.
Bioorganic & Medicinal Chemistry|August 24, 2025
Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interactionYang Yang, Meiqin Xu, Ke Wang, et al.
Oncotargets and Therapy|July 10, 2018
CAT<sub>3</sub>, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O<sup>6</sup>-methylguanine DNA methyltransferase expressionMing Ji, Liyuan Wang, Ju Chen, et al.
Free Radical Biology & Medicine|April 8, 2014
Involvement of Na/K-ATPase in hydrogen peroxide-induced activation of the Src/ERK pathway in LLC-PK1 cellsYu Wang, Qiqi Ye, Changxuan Liu, et al.
Acta Pharmaceutica Sinica. B|July 31, 2023
Erratum: Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858]Fangfang Lai, Ming Ji, Lei Huang, et al.
Pageof 7